Применение рекомбинантного активированного протеина С в терапии сепсиса у детей после кардиохирургических вмешательств
https://doi.org/10.15360/1813-9779-2008-2-52
Аннотация
Об авторах
Е. Ю. ОчаковскаяА. В. Харькин
Г. В. Лобачева
Н. Н. Самсонова
Л. Г. Климович
Л. А. Бокерия
Список литературы
1. Goldstein B., Simon N., Peters M. et al.
2. Watson R. S, Carcillo J. A, Linde-Zwirble et al.The epidemiology of severe sepsis in children in the United States. Amer. J. Respir. Crit. Care Med. 2003; 167: 695—701.
3. Graf J., Doig G. S., Cook D. J. et al.Randomizes, controlled clinical trials in sepsis: Has methodological quality improved over time? Crit. Care Med. 2002; 30 (2): 461—472.
4. Dellinger R. P., Carlet J. M, Masur H. et al.Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Crit. Care Med. 2004; 32: 858—873.
5. Bernard G. R, Vincent J. L, Laterre P. F. et al.Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 2001; 344: 699—709.
6. RiewaldM, Petrovan R.J., Donner A. et al.Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 2002; 296: 1880—1882.
7. Joyce D. E., Gelbert L., Ciaccia A. et al.Gene expression profile of an tithrombotic protein C defines new mechanisms modulating inflammation and apoptosis. J. Biol. Chem. 2001; 276: 11199—11203.
8. Dhainaut J. F., Laterre P. F., Janes J. M. et al.Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multipleorgan dys-funtion: data from the PROWESS trial. Intens. Care Med. 2003; 29: 894—903.
9. Ely E. W., Laterre P. F., Angus D. C. et al.Drotrecogin alfa (activated) administration across clinical important subgroups of patients with severe sepsis. Crit. Care Med. 2003; 31: 121
10. Schein R. M. H., Kinasewitz G. T.Risk/benefit analysis for drotrecogin alfa (activated). Am. J. Surg. 2002; 184(suppl.): 25S—38S.
11. Bernard G., Macias W. L., Joyce D. E. et al.Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis. Crit. Care 2003; 7: 155—163.
12. US food and drug administration: Drotrecogin alfa (activated), Xigris, BLA #125029/0. FDA briefing information. US food and drug administration; 6 August 2001. [http://www.fda.gov/cber/label/droteli112101LB.pdf].
Рецензия
Для цитирования:
Очаковская Е.Ю., Харькин А.В., Лобачева Г.В., Самсонова Н.Н., Климович Л.Г., Бокерия Л.А. Применение рекомбинантного активированного протеина С в терапии сепсиса у детей после кардиохирургических вмешательств . Общая реаниматология. 2008;4(2):52. https://doi.org/10.15360/1813-9779-2008-2-52
For citation:
Ochakovskaya Y.Yu., Kharkin A.V., Lobacheva G.V., Samsonova N.N., Klimovich L.G., Bockeria L.A. Use of Recombinant Activated Protein C in Therapy for Sepsis in Children after Cardiosurgical Interventions . General Reanimatology. 2008;4(2):52. (In Russ.) https://doi.org/10.15360/1813-9779-2008-2-52